Gady Cojocaru
Research Subjects
Gady Cojocaru has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Eran Ophir
Compugen, Ltd., Holon, Israel
43 shared publications - Masha Frenkel
Compugen, Ltd., Holon, Israel
43 shared publications - Adva Levy-Barda
Rabin Medical Center 2 Biobank, Department of Pathology Petah Tikva, Israel
42 shared publications - Eran Sadot
Rabin Medical Center 6 Department of Surgery Petach Tikva, Israel
42 shared publications - Pierre Ferre
Compugen Ltd., Holon, Israel. 1
42 shared publications - Ram Eitan
Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
42 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S5. IL-18BP blockade alters the immune infiltrate composition of E0771 tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S5. IL-18BP blockade alters the immune infiltrate composition of E0771 tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S4. Anti-IL-18BP Ab induced immunogenic memory response in E0771 tumor model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S4. Anti-IL-18BP Ab induced immunogenic memory response in E0771 tumor model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S1. IL-18BP is a potential soluble immune checkpoint in cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S1. IL-18BP is a potential soluble immune checkpoint in cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S3. Antitumor activity of anti-mouse-IL-18BP Ab in mice studies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S3. Antitumor activity of anti-mouse-IL-18BP Ab in mice studies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S2. COM503 releases IL-18 activity in biochemical and functional assays.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Supplemental Figure S2. COM503 releases IL-18 activity in biochemical and functional assays.